Turkey Pharmaceuticals and Healthcare Report Q1 2016

97 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: A strong health care sector and more certain drug pricing policy will drive pharmaceutical
sales in value terms over the next 10 years and improve the commercial opportunities for pharmaceutical
manufacturers. Despite this positive development, cost containment measures will remain a risk, as will the
political situation with neighbouring Syria and nearby Russia.
Headline Expenditure Projections
? Pharmaceuticals: TRY18.72bn (USD8.56bn) in 2014 to TRY20.81bn (USD7.38bn) in 2015; +11.1% in
local currency and -13.8% US dollar terms. Forecast unchanged in local currency and down in US
dollars compared with previous quarter due to revised exchange rate expectations.
? Healthcare: TRY95.78bn (USD43.78bn) in 2014 to TRY107.17bn (USD38.01bn) in 2015; +11.9% in
local currency and -13.2% US dollar terms. Forecast unchanged in local currency and down in US
dollars compared with previous quarter due to revised exchange rate expectations.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Turkey 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Turkey 2011-2019) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Turkey 2013-2019) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Turkey 2013-2019) 30
Industry Risk/Reward Index 31
Central And Eastern Europe Risk/Reward Index - Q1 2016 31
Turkey Risk/Reward Index 38
Rewards 38
Risks 39
Regulatory Review 41
Intellectual Property Regime 42
Market Access Issues 45
Pricing Regime 47
Table: Turkish Pharmaceutical Pricing Decrees 48
Reimbursement Regime 49
Table: Pharmacist Discount Related To Annual Sales Revenue (VAT Excluded) 51
Market Overview 52
Market Overview 52
Epidemiology 53
Healthcare Sector 54
Health Insurance 55
Healthcare Infrastructure 55
Healthcare Financing 57
Table: Healthcare Resources (Turkey 2009-2014) 58
Table: Healthcare Personnel (Turkey 2009-2014) 58
Table: Healthcare Activity (Turkey 2009-2014) 59
Research & Development 59
Clinical Trials 61
Competitive Landscape 62
Pharmaceutical Sector 62
Research-Based Industry 63
Generic Drugmakers 64
Company Activity 66
Table: Multinational Market Activity 66
Pharmaceutical Distribution 67
Pharmaceutical Retail 68
Company Profile 70
Abdi Ibrahim 70
EastPharma (Deva) 74
Eczacibasi Healthcare 77
Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals 80
Sanovel Pharmaceuticals 83
Demographic Forecast 86
Table: Population Headline Indicators (Turkey 1990-2025) 87
Table: Key Population Ratios (Turkey 1990-2025) 87
Table: Urban/Rural Population & Life Expectancy (Turkey 1990-2025) 88
Table: Population By Age Group (Turkey 1990-2025) 88
Table: Population By Age Group % (Turkey 1990-2025) 89
Glossary 91
Methodology 93
Pharmaceutical Expenditure Forecast Model 93
Healthcare Expenditure Forecast Model 93
Notes On Methodology 94
Risk/Reward Index Methodology 95
Index Overview 96
Table: Pharmaceutical Risk/Reward Index Indicators 96
Indicator Weightings 97

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Turkey 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Turkey 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Turkey 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Turkey 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Turkey 2013-2019)
Table: Turkish Pharmaceutical Pricing Decrees
Table: Pharmacist Discount Related To Annual Sales Revenue (VAT Excluded)
Table: Healthcare Resources (Turkey 2009-2014)
Table: Healthcare Personnel (Turkey 2009-2014)
Table: Healthcare Activity (Turkey 2009-2014)
Table: Multinational Market Activity
Table: Population Headline Indicators (Turkey 1990-2025)
Table: Key Population Ratios (Turkey 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Turkey 1990-2025)
Table: Population By Age Group (Turkey 1990-2025)
Table: Population By Age Group % (Turkey 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015
    BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality health serv...
  • Latvia Pharmaceuticals and Healthcare Report Q1 2016
    BMI View: The development of Latvia's market will be shaped by an increased emphasis on generic drugs; an implication of fiscal austerity measures. As a result, despite its transparent regulatory policies and business-friendly operating environment, the Latvian pharmaceutical market will continue to remain a modest prospect for drugmakers. Exports will also be impacted by regional tensions. Headline Expenditure Projections ? Pharmaceuticals: EUR319mn (USD428mn) in 2014 to EUR338mn (USD372mn) in ...
  • Lebanon Pharmaceuticals and Healthcare Report Q1 2016
    BMI View: We hold a bullish outlook for Lebanon's pharmaceutical market, the government's commitment to improving healthcare access coupled with a rising non-communicable disease burden will be a key driving factor for growth over the long-term. However, economic stagnation and political uncertainty made worse by the ongoing civil war in Syria will add downward pressure on our forecast. Headline Expenditure Projections ? Pharmaceuticals: LBP2.31trn (USD1.53bn) in 2014 to LBP2.47trn (USD1.63bn) i...
  • Iran Pharmaceuticals and Healthcare Report Q1 2015
    BMI View: BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market to contract sharply in US dollar terms. While improved international relations have reduced the regulatory risk associated with operating in the market for multinational drugmakers, the recent proclamation of the Islamic State (IS) in neighbouring Iraq and S...
  • Jordan Pharmaceuticals and Healthcare Report Q1 2016
    BMI View: Jordan offers an attractive pharmaceutical market for multinational drugmakers, although its potential will remain impeded by the ongoing political and economic instability in neighbouring Syria - which is having a detrimental impact on Jordan's healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: JOD643mn (USD905mn) in 2014 to JOD683mn (USD962mn) in 2015; +6.3% in local currency terms and US dollar terms. Forecast unchanged from Q415. ? Healthcare: JOD1.86bn (USD2.62...